HHC
BIO icon

Hutchin Hill Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hutchin Hill Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,000
Closed -$667K – 414
2017
Q3 		$667K Buy
+3,000
New +$675K 0.03% 448
2017
Q2 		– Sell
-2,500
Closed -$498K – 838
2017
Q1 		$498K Buy
+2,500
New +$482K 0.01% 656
2015
Q1 		– Sell
-21,100
Closed -$2.54M – 670
2014
Q4 		$2.54M Buy
21,100
+10,400
+97% +$1.2M 0.09% 202
2014
Q3 		$1.21M Sell
10,700
-200
-2% -$23.7K 0.05% 339
2014
Q2 		$1.3M Buy
+10,900
New +$1.33M 0.06% 289

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HCM
Hitchwood Capital Management New York $184M AUM 3.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Hutchin Hill Capital's BIO Position: Q4 2017 in Review

Hutchin Hill Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2017, closing a stake of 3,000 shares — an estimated $667K sold.

Hutchin Hill Capital first reported a position in BIO in Q2 2014 and held it in 5 quarters. The position peaked at $2.54M in Q4 2014. 302 funds tracked by Wall St. Rank hold BIO as of Q4 2017.

  • Hutchin Hill Capital reported no remaining Bio-Rad Laboratories Class A position as of Q4 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 3,000 Bio-Rad Laboratories Class A shares in Q4 2017, an estimated $667K.
  • Hutchin Hill Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2014 and held it in 5 quarters.
  • Hutchin Hill Capital's Bio-Rad Laboratories Class A position peaked at $2.54M in Q4 2014.
  • 302 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.